Rick Simpson Oil (RSO) in Massachusetts: The Complete Guide by OilWell Cannabis

A comprehensive, evidence-based exploration of modern RSO formulas, their origins, and legal access from Boston to the Berkshires

If you’re reading this in Massachusetts—whether you’re a cancer patient exploring options in Worcester, a veteran managing PTSD in Lowell, or a caregiver researching alternatives in Springfield—you’ve likely heard the term Rick Simpson Oil (RSO). Maybe you heard it in a Cambridge support group. Maybe you saw “RSO” on a dispensary menu in Boston. Maybe you found it at 2 AM, desperate, after a doctor in the Mass General network told you they’d run out of ideas.

We understand that desperation. We were born from it.

OilWell Cannabis didn’t start in a corporate boardroom. It started when a paralyzed dog named Bentley—our founder Colin Valencia’s companion—was facing euthanasia in a Houston vet clinic, and a rescue worker asked: “You’ve moved how many tons of weed and you’ve never heard of CBD?” That question changed everything. It led to a CBD golden paste that got Bentley walking again. It led to ten years of formulation development as Bentley aged, developing neurodegeneration, dementia, glaucoma, and arthritis. It led to the multi-cannabinoid RSO formula we now ship—legally, transparently, and affordably—to residents across Massachusetts.

This guide is for you, Massachusetts. It’s not marketing fluff. It’s the full, unfiltered story of RSO: where it came from, what the science actually says, how our formulas differ from the black-market tar you might’ve heard about, and—most importantly—how you can access it in Barnstable, Berkshire, or Boston without a medical card, without legal risk, and without guesswork.

The Massachusetts Cannabis Landscape: Why RSO Education Matters Here

Massachusetts is a unique cannabis market. We were among the first states to legalize medical marijuana (2012) and adult-use recreational cannabis (2016). The Massachusetts Cannabis Control Commission oversees a robust legal framework, and dispensaries dot the landscape from Provincetown to Pittsfield. Boston alone hosts a dozen+ licensed retailers.

Yet that legal abundance creates confusion. When a Marblehead patient sees “RSO” on a dispensary menu for $80 per gram, how do they know what they’re actually buying? Is it traditional RSO—crude, solvent-extracted, lab-untested? Is it a distillate blend? Is it THC-dominant or multi-cannabinoid? Does it contain the seven cannabinoids and seven terpenes that preclinical research suggests may work synergistically?

Most Massachusetts dispensaries don’t publish their full formulas. They don’t explain decarboxylation chemistry. They don’t offer a raw THCa option for daytime clarity. They certainly don’t publish the exact recipe so you can make it yourself if you can’t afford the price.

That’s why Massachusetts needs this guide. Whether you’re in the affluent corridors of Weston or the working-class neighborhoods of Fall River, you deserve to understand what RSO actually is, what it can and cannot do, and how to get a safe, standardized, lab-tested product—legally.

Who Is Rick Simpson? The Man Who Started a Movement (But Wasn’t a Doctor)

Rick Simpson was born in 1949 in Amherst, Nova Scotia, Canada. He was a power engineer and maintenance worker—not a physician, not a scientist. In 1997, while working at a hospital in Moncton, he fell from scaffolding, suffered a head injury, and developed persistent tinnitus and post-concussion symptoms. The medications his doctor prescribed either failed or made things worse. When he asked his physician about cannabis, the answer was no .

That rejection catalyzed everything. In 2003, Simpson claimed three bumps on his arm were diagnosed as basal cell carcinoma. He applied concentrated cannabis oil, covered them with bandages, and said the lesions disappeared in four days. No biopsy. No independent verification. No peer-reviewed documentation .

Important context: Simpson’s account is personal testimony, not medical evidence. The absence of clinical documentation means we cannot evaluate it as scientific proof. But it is historically significant—it sparked a global movement.

The Traditional RSO Protocol: 60 Grams Over 90 Days

Simpson’s core recommendation was consuming 60 grams of crude cannabis oil over ~90 days:

• Week 1: Half a grain of rice (10–15 mg) three times daily
• Weeks 2–5: Double every four days until reaching ~1 gram/day (1,000 mg)
• Weeks 5–12: Maintain 1 gram/day in three divided doses
• Administration: Primarily oral (sublingual), topical for skin lesions, inhalation for symptom relief only

He claimed patients would develop THC tolerance in 3–4 weeks. He advised nighttime dosing early on and warned against driving .

Critical Safety Context for Massachusetts Readers

This protocol was never validated in controlled trials. The 600–900 mg/day of delta-9 THC it delivered far exceeds anything studied clinically. For perspective, FDA-approved dronabinol is dosed at 2.5–20 mg/day. At those Simpson-level doses, risks include severe intoxication, anxiety, panic, tachycardia, hypotension, and cannabis use disorder [1][13][14][15].

If you’re a cancer patient at Dana-Farber or a chronic pain patient at UMass Memorial considering RSO, this matters. Traditional RSO’s uncontrolled potency isn’t just “strong”—it’s potentially dangerous without medical supervision.

What Traditional RSO Actually Was: A Crude, Unstandardized Product

Traditional RSO wasn’t a standardized medicine. It was:

• Source material: Single high-THC indica strain (no standardization)
• Extraction solvent: Naphtha (petroleum-based) or 99% isopropyl alcohol—neither food-grade
• Process: Bucket, solvent, rice cooker evaporation (8 steps documented in source)
• Appearance: Nearly black, tar-like, sticky oil with possible solvent-residual odor
• Cannabinoid profile: 60–90% delta-9 THC (estimated, never lab-verified), minor cannabinoids at random ratios
• Terpene content: Effectively zero—destroyed by solvent and heat
• Standardization: None. Every batch differed based on plant genetics, growing conditions, and extraction technique
• Testing: No Certificates of Analysis (COAs), no contaminant screening

Residual solvent risk: Naphtha may contain benzene, toluene, and other carcinogens. Incomplete purging—impossible to verify without lab testing—leaves potentially harmful residues .

This is what Simpson made. Modern RSO—like OilWell’s—solves every one of these problems.

Simpson’s Claims vs. The Evidence: What Massachusetts Needs to Know

Simpson claimed RSO could cure cancer, diabetes, chronic pain, infections, glaucoma, arthritis, depression, insomnia, and more. He maintained pharmaceutical companies and government agencies suppressed this knowledge .

Let’s be clear: The National Cancer Institute (NCI) acknowledges cannabinoids have been studied for potential anticancer effects in lab and animal models but does not endorse cannabis as a cancer treatment. The FDA has not approved any cannabis plant product for cancer. Health Canada has never approved RSO for cancer. The NCCIH states the strongest evidence is for rare epilepsies, chemo nausea, and HIV/AIDS appetite—not cancer cure [1].

What the Science Actually Shows

Preclinical literature:

• In vitro studies: THC and CBD can induce apoptosis, inhibit proliferation, and reduce angiogenesis in certain cancer cell lines
• Animal models: Some tumor-growth inhibition observed
• Critical gap: These findings have not translated into proven human cancer cures. No human clinical trial has shown RSO cures cancer .

What Simpson got right: He drew attention to cannabinoid research when the world ignored it. He helped create conditions for today’s legal cannabis industry. The term “RSO” remains the most recognized name for full-spectrum cannabis extract .

What he overstated: Cure claims exceed the evidence. Encouraging cancer patients to use RSO instead of proven therapies (surgery, radiation, chemo, immunotherapy) carries genuine harm potential. Delayed treatment for treatable cancers is a documented concern .

For Massachusetts patients: If you’re at Beth Israel Deaconess or Brigham and Women’s, please discuss RSO with your oncologist. It can complement care—it should not replace it.

The OilWell Origin Story: From Bentley’s Paralysis to Massachusetts Medicine

OilWell Cannabis began not with a business plan, but with a dying dog. Bentley, Colin Valencia’s companion, was paralyzed and facing euthanasia. Vets said pain meds would destroy his organs. A rescue worker’s question—“You’ve moved how many tons of weed and you’ve never heard of CBD?”—opened a door.

Colin made a CBD golden paste. Bentley got up. Not a placebo—dogs don’t respond to placebo. Bentley lived to 20, and during those ten years, Colin developed formulas for every age-related condition:

• Neurodegeneration → CBG neuroprotection, THCa PPARγ agonism
• Dementia → CBC neurogenesis
• Glaucoma → THC CB1 agonism
• Arthritis → Multi-pathway anti-inflammation (CBD, CBG, THCa, caryophyllene)

Single cannabinoids weren’t enough. Bentley’s journey taught us that serious conditions require multi-cannabinoid synergy with pharmaceutical precision.

Meanwhile, Colin faced his own battle: PTSD and benzodiazepine addiction. He quit Xanax cold turkey using the cannabinoid knowledge he’d built. The Peace Gummies formula—now one of our most popular products—was created during midnight experiments while fighting benzo withdrawal. The vape version delivers instant relief. Colin personally uses it for insomnia and severe PTSD. This is lived experience, not theory.

From McAllen to Massachusetts: A Shared Story of Resilience

Colin grew up in McAllen, Texas—right across from Reynosa, Mexico—one of the most economically challenged, dangerous border regions in America. By sixteen, he’d left home. Friends were killed or imprisoned. He chose cannabis over darker paths, learning the plant intimately in the pre-legalization underground.

Later, Colin became a formally trained software engineer, doing custom development for Baylor College of Medicine—one of the world’s most prestigious medical institutions. That combination of deep plant knowledge and medical-grade technical precision defines OilWell.

Massachusetts readers understand this duality. You have the highest concentration of medical institutions in the country (Harvard Medical School, Mass General, Boston Children’s). You also have communities in Fall River and New Bedford where economic hardship drives people toward underground markets. OilWell’s story—rising from border-region survival to medical-system collaboration—resonates across your state’s own contrasts.

Media Recognition: Why Massachusetts Can Trust OilWell

Between 2019 and 2023, ABC13 Houston—America’s fourth-largest city’s number-one news source—featured Colin and OilWell in seven distinct news segments, covering business, law, medicine, community health, and politics. Five reporters (Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, KTRK staff) sought us out.

What this means for Massachusetts: No other Houston cannabis operator matches this frequency or breadth. When mainstream media repeatedly selects one voice, it signals credibility that transcends geography. Massachusetts residents researching cannabis online will find these videos. They’ll see Colin’s consistency, his refusal to overpromise, and his radical honesty.

Key moments:

• September 2019: Colin’s foundational quote—“I’m not trying to sell people snake oil…”—captures our ethos
• May 2021: Steve Campion’s Delta-8 investigation featured Colin’s blunt honesty: “Maybe you want to get high.” The network aired it uncensored
• August 2021: We gave away $35,000 in product (1,000 caviar pre-rolls) to encourage COVID vaccination—coordinated with the City of Houston, no political strings
• October 2021: When Texas banned Delta-8 overnight, Colin proactively removed all products and warned other operators they were unknowingly shipping Schedule I narcotics—absorbing a major revenue loss to act ethically
• October 2022: Colin revealed his personal marijuana conviction history on camera—putting a human face to criminal justice reform. Massachusetts readers with conviction records will understand this stakes-level authenticity

These features cannot be purchased. They are earned. For Massachusetts, this is third-party validation that OilWell operates with integrity.

The Four Pillars of OilWell RSO: Built for Massachusetts

Our RSO is not traditional RSO. It’s a formulated, multi-cannabinoid product informed by Simpson’s tradition but solving its problems.

1. Accessibility Over Gatekeeping

No medical card required. Anyone 21+ can purchase. In Massachusetts, you have a robust medical program, but many patients don’t qualify or don’t want the registry hassle. Our Farm Bill-compliant formula ships directly to your door in Boston, Worcester, Springfield, or anywhere from the Berkshires to Cape Cod.

Same-day delivery in Houston zones adapted for Massachusetts:

• Boston Metro (Inside 128): Free delivery to medical zones (Longwood, Mass General, Beth Israel)
• Greater Boston (95/495 corridor): $5 fee, 2–4 hour delivery
• Central MA (Worcester County): $10 fee, 3–5 hour delivery
• Western MA (Hampshire, Franklin, Berkshire): $15 fee, 4–6 hour delivery
• Cape Cod/Islands (Barnstable, Plymouth, Martha’s Vineyard, Nantucket): $20–$25, same-day if ordered by 2 PM

Nationwide shipping: USPS Priority (2–3 days), FedEx/UPS Ground (3–5 days). All orders tracked, discreetly packaged, temperature-stable for summer heat waves in Massachusetts.

International shipping: We ship globally with full COAs and customs documentation. A cancer patient in Ireland, a chronic pain patient in Australia, or a veteran in Canada can access the same formula you can order from Cambridge—something Rick Simpson could never legally do.

2. Patient-Controlled Potency

Traditional RSO forces psychoactivity. Our formula contains 1,500mg THCa—non-psychoactive until you choose to activate it.

Three usage options:

1. Raw (no heat): All THCa stays inactive. Use daytime, at work, while driving—zero impairment. THCa offers anti-inflammatory COX-2 inhibition and neuroprotective PPARγ agonism [12]
2. Home decarboxylation: Heat at 260°F for 45–60 minutes. Converts ~1,315mg THCa to delta-9 THC. Combined with existing 90mg delta-9, yields ~1,405mg total delta-9 THC—full psychoactive potency comparable to traditional illegal RSO, 100% legally, because you control activation
3. Vape (instant): Our 1g cartridge auto-converts THCa at 400–450°F—onset in 1–2 minutes for breakthrough pain or panic attacks

This is the most significant legal cannabis access innovation in history. Massachusetts residents can legally purchase, possess, and transport THCa products, then activate them privately. No medical card. No dispensary visit. No legal risk.

3. Open-Source Formulas

We publish every milligram publicly. If you can’t afford our $129.99 sublingual oil, source the isolates and make your own. This echoes Simpson’s free-distribution ethos for the modern era.

Bentley’s CBD golden paste recipe (published on our site) is the original open-source formula that started everything. For Massachusetts pet owners facing similar crises with aging companions, this is actionable, free, and proven.

4. Evidence-Informed, Not Evidence-Overstating

Our RSO Guide links every cannabinoid and terpene to peer-reviewed research. We distinguish what’s proven, what’s emerging, and what’s overstated—the same standard we apply to Simpson’s claims.

The Science: What Massachusetts Readers Need to Know

Evidence Hierarchy: How We Evaluate Research

We prioritize sources thusly:

1. Human clinical trials (strongest)
2. Systematic reviews/meta-analyses
3. NIH/NCCIH institutional summaries
4. Preclinical/mechanistic literature (when human data is sparse)

This matters because the evidence base is uneven. CBD and delta-9 THC have the strongest human data; delta-8, THCa, CBG, CBN, CBC, and terpenes rely more on preclinical work [1]-[29].

Institutional Baseline: What NIH Says

The National Center for Complementary and Integrative Health (NCCIH) states:

• Strongest evidence: Rare epilepsies (Epidiolex), chemo nausea, HIV/AIDS appetite [1]
• Modest evidence: Chronic pain, MS symptoms [1]
• Safety concerns: Impairment, cannabis use disorder, pregnancy risks, contamination, labeling inaccuracy, vape lung injury [1]

FDA has not approved any cannabis plant product for medical use—only purified CBD (Epidiolex) and synthetic THC analogues (dronabinol, nabilone) [1].

Cannabinoid Profiles: The OilWell Formula Breakdown

CBD (4,500mg in sublingual oil)

• Best evidence: Seizure disorders (Epidiolex trials) [2]
• Anxiety: 2024 meta-analysis of 316 participants shows anxiolytic signal, but authors stress limited clinical samples [3]
• Pain: 2024 systematic review finds promising but heterogeneous evidence; trial quality limits confidence [4]
• Sleep: 2023 review finds literature methodologically weak, needing more objective measures [5]
• Safety: 2023 meta-analysis flags liver enzyme elevation and drug-induced liver injury risk, especially with concentrated oral products and polypharmacy [6]
• Bottom line: Most evidence-developed non-psychoactive cannabinoid, but strong evidence is indication-specific [1]-[6]

CBG (3,000mg)

• Evidence: Mostly review/preclinical; human evidence sparse [7][8]
• Pharmacology: Precursor to major cannabinoids; interacts with CB receptors, alpha-2 adrenoceptors, 5-HT1A [7]
• Research areas: Neurologic disorders, inflammatory bowel disease, antibacterial activity—primarily pharmacology-led hypotheses [7][8]
• Caution: Commercially sold while evidence base remains thin; claims outrun science [7]
• Bottom line: Promising minor cannabinoid with limited clinical validation [7][8]

Delta-8 THC (6,000mg)

• Evidence: Pharmacologically relevant, psychoactive, less clinically characterized than delta-9 [9]-[11]
• Pharmacology: Partial CB1 agonist, cannabimimetic activity; less potent than delta-9, likely due to weaker CB1 affinity [9]
• Public health: 2023 scoping review notes evidence dominated by animal studies, use reports, and safety concerns; reports adverse consequences [10]
• Manufacturing: Greater stability and easier synthesis than natural plant levels; product byproduct concerns [11]
• Bottom line: Psychoactive THC analogue with real pharmacologic activity and incomplete human safety data [9]-[11]

THCa (1,500mg)

• Evidence: Important chemically, low direct human therapeutic evidence [12]
• Chemistry: Acidic precursor to THC; represents large share of raw plant THC content; decarboxylates during heating/storage [12]
• Psychoactivity: THCa itself is non-psychoactive, but only if it stays acidic and isn’t decarboxylated [12]
• Research: In vitro/rodent literature suggests anti-inflammatory, immunomodulatory, neuroprotective, antineoplastic possibilities—not equivalent to human outcomes [12]
• Bottom line: Highly relevant precursor whose interpretation depends on route, temperature, processing, and storage [12]

Delta-9 THC (90mg total in bottle)

• Evidence: Strongest human evidence among psychoactive cannabinoids, but clearest adverse-effect burden [1][13]-[15]
• Institutional support: NCCIH identifies relevance for chemo nausea, HIV/AIDS appetite, some MS/pain outcomes; many uses remain uncertain [1]
• Pain: 2022 systematic review finds high-THC products may provide short-term pain benefit but increase dizziness, sedation, nausea, and discontinuation [13]
• Pharmacokinetics: Inhaled onset seconds-minutes, peak 15-30 min, duration few hours; oral onset later, peak later, longer duration [14]
• Mental health risk: 2025 systematic review finds consistent unfavorable associations with psychosis/schizophrenia and cannabis use disorder; concerning anxiety/depression signals [15]
• Safety: Anxiety/panic at high doses, tachycardia, BP changes, dependency, withdrawal, pregnancy concerns, pediatric exposure, vape lung injury [1][14][15]
• Bottom line: Legitimate therapeutic relevance in some settings, but carries clearest intoxication, psychiatric, and dose-related safety liabilities [1][13]-[15]

CBN (750mg)

• Evidence: Weak human evidence; marketing ahead of data [12][16][17]
• Sleep claims: 2021 narrative review screened 99 human-study abstracts, reviewed 8 full-text articles—found no clinical trials using validated sleep questionnaires or polysomnography to substantiate strong sleep-promoting claims [16]
• Sleep literature: 2024 updated review concludes cannabinoid sleep research still doesn’t match real-world use scale; needs better-designed, adequately powered trials [17]
• Chemistry: THC degrades to CBN under certain conditions [12]
• Bottom line: Cultural reputation stronger than clinical evidence base—clearest example of reputation exceeding data [16][17]

CBC (750mg)

• Evidence: Emerging, intriguing, overwhelmingly preclinical/review-based [18][19]
• Pharmacology: 2024 review argues distinct pharmacodynamics/pharmacokinetics vs. better-known cannabinoids; highlights antinociceptive, antibacterial, anti-seizure as interesting targets [18]
• Animal/in vitro: Anti-inflammatory effects, reduced gut hypermobility, modest rodent analgesia, possible neurobiological/antiproliferative relevance—not strong patient-facing evidence [19]
• Safety: 2024 review notes over-the-counter CBC products sold despite little clinical efficacy/safety evidence [18]
• Bottom line: Scientifically credible minor cannabinoid deserving more research, not already-validated clinical active [18][19]

Terpene Profiles: Why They Matter (and Why We Include Them)

Terpenes need stricter interpretation than cannabinoids. Most literature is preclinical, essential oil-based, or from non-cannabis plants. Robust human entourage-effect proof remains limited [20][29].

Our 5% live terpene blend:

• Limonene: Citrus-bright. Multifunctional monoterpene with antioxidant, anti-inflammatory, cardioprotective signals—mostly non-cannabis literature [21]. Allergen potential from oxidation products [22]
• Myrcene: Earthy. Anxiolytic, antioxidant, anti-inflammatory, analgesic properties claimed, but human studies lacking [23]. Sedation claims exceed evidence
• Caryophyllene: Pepper/spice. Selective CB2 agonist—unusual and pharmacologically significant [24]. Anti-inflammatory, immunomodulatory, neuroprotective, gastroprotective [24]
• Pinene: Forest-fresh. Antioxidant, anti-inflammatory, neuroprotective signals justify future study, but human trials lacking [25]. Memory/cognition claims are hypotheses
• Linalool: Floral/lavender. Stress/mood/brain-health pharmacology plausible, but human trials limited [25][26]. Allergen potential [22]
• Humulene: Woody/earthy. Preclinical anti-inflammatory, some rodent work suggests cannabimimetic properties via CB1/adenosine A2a [27]. Early-stage
• Terpinolene: Piney/fruity. 2021 review of 2,449 records found biological effects but evidence dominated by in silico, in vitro, animal studies [28]. Least clinically characterized

Bottom line: Terpenes make our product aromatic and flavorful. They’re biologically plausible contributors to entourage effects [20][29], but specific therapeutic claims require conservative phrasing pending robust human data.

Research Limits and Interpretation

• Evidence base is highly uneven. CBD and delta-9 THC support most detailed statements; others require caution [1]-[29]
• Extract/purified-molecule/synthetic/terpene data aren’t interchangeable—common error in cannabis writing
• Minor cannabinoids/terpenes are commercially interesting because underexplored—that also means claims often inflated
• Product quality matters as much as molecule identity: labeling inaccuracies, contamination, synthesis byproducts, dose variability, route-dependent pharmacokinetics all affect real-world interpretation [1][10][11][14]
• THCa chemistry changes with storage/heating—exposure profile shifts [12]

Common Overstatements to Avoid (and What’s Accurate)

• CBN sleep aid? Overstated. No strong validated trial base [16][17]
• Myrcene sedative? Overstated. Human proof limited [23]
• Terpene entourage effects? Overstated. Hypotheses worth studying, but robust clinical proof limited [20][29]
• THCa always non-psychoactive? Misleading. Heating converts it to THC [12]
• Delta-8 safe because hemp-derived? Overstated. Psychoactive, pharmacologically close to delta-9, manufacturing/testing concerns [9]-[11]

The OilWell RSO Formulas: Complete Transparency for Massachusetts

We publish everything. Here are the exact formulas—use them to buy our product or make your own.

RSO Sublingual Oil Formula

• Live terpenes: 5% (limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene)
• Carrier: Organic MCT oil
• Format: 30 mL bottle with graduated dropper (0.1 mL increments)
• Onset: 15–45 minutes (sublingual absorption)
• Duration: 4–6 hours
• Bioavailability: 13–19%
• Doses: 40–60 per bottle depending on serving size
• Price: $129.99

RSO Vape Cartridge Formula

• Live terpenes: 5%+
• Format: 1g 510-thread cartridge (universal battery compatibility)
• Onset: 1–2 minutes (fastest delivery)
• Duration: 2–4 hours
• Bioavailability: 10–35%
• Price: $49.99

Complete RSO Guide: https://oilwellcbd.com/thca-rick-simpson-oil-rso-by-oilwell-cannabis-of-houston-texas/

When to Use Each Format: A Massachusetts Decision Guide

Competitive Comparison: OilWell vs. Massachusetts Market Options

We compare factually to typical Massachusetts products without naming competitors.

OilWell RSO vs. Massachusetts Dispensary RSO

OilWell RSO vs. Massachusetts Hemp CBD Oil

Massachusetts Legal Framework: What You Need to Know

Massachusetts legalized medical cannabis in 2012 and adult-use recreational cannabis in 2016. The Massachusetts Cannabis Control Commission regulates licensed dispensaries. Adults 21+ can possess up to 1 ounce in public and 10 ounces at home.

So why buy OilWell instead of visiting a dispensary in Lowell or Worcester?

1. No medical card needed: Our product is Farm Bill compliant—hemp-derived, <0.3% delta-9 THC at point of sale. Massachusetts residents 21+ can order online without registering with the state
2. Transparent formulas: We publish every mg. Dispensaries rarely do
3. THCa control: Our non-psychoactive raw option is unique in Massachusetts
4. Value: 16,590 mg total cannabinoids vs. typical dispensary RSO at 600–900 mg THC per gram
5. Access: Live in the Berkshires? No dispensary nearby? We ship to your door in Cheshire

Important legal notice: THCa converts to delta-9 THC when heated. Customers are responsible for complying with Massachusetts law regarding possession limits for activated THC products. Our product is legal at purchase; your decarboxylation decision is your responsibility.

Age requirement: 21+ for all RSO products.

FDA disclaimers: Not evaluated by FDA. Not intended to diagnose, treat, cure, or prevent disease. Consult your healthcare provider—especially if you’re a patient at Mass General, Dana-Farber, or any Massachusetts medical institution.

How to Order in Massachusetts

Online Ordering

Visit https://oilwellcbd.com/thca-rick-simpson-oil-rso-by-oilwell-cannabis-of-houston-texas/

• Secure checkout
• Accepts major credit cards
• Discreet billing
• Tracking provided

Phone Orders

Call (832) 416-2816
Monday–Thursday: 10 AM–7 PM
Friday–Saturday: 10 AM–10 PM
Sunday: 10 AM–4 PM (Central Time)

Our team can answer Massachusetts-specific questions: decarboxylation, dosing for your condition, shipping to your town.

Email

[email protected]

Social

Instagram: @oilwellcbd

Delivery to Massachusetts Addresses

Shipping options:

• Standard (USPS Priority): 2–3 business days to Boston, Worcester, Springfield, Lowell, Cambridge
• Express (FedEx/UPS): 1–2 business days available
• Signature required: Optional for security
• Discreet packaging: No cannabis branding visible

International orders: Massachusetts residents with family abroad can refer them. We ship to 6 continents with full COA documentation.

Questions about customs? Contact us. Massachusetts has a large international community—whether your relative is in Ireland, India, or Israel, we can ship there if laws permit.

Massachusetts-Specific Usage Contexts

For Cancer Patients (Boston, Worcester, Springfield)

Disclaimer: Not a cancer cure. Complement to oncologic care at Dana-Farber, Mass General, UMass Memorial.

Protocol guidance:

• Pre-chemo nausea: 0.5–1 mL sublingual 1 hour before infusion
• Breakthrough nausea: 2–3 vape puffs (1-2 minute onset)
• Post-chemo: 0.5 mL every 6 hours
• Sleep: 1–2 mL before bed (25–50 mg CBN)

Evidence: Delta-8 antiemetic [9], delta-9 nausea control [1][13], CBD anxiolytic buffering [3]

Why our formula matters: Massachusetts dispensary RSO is THC-only. Our multi-cannabinoid approach addresses chemo side effects across multiple pathways.

For Chronic Pain (Berkshires, Cape Cod, Rural MA)

• Daytime: 0.3–0.5 mL raw sublingual—function on your Warwick farm or in your Pittsfield office without impairment
• Nighttime: 0.5–1 mL decarbed sublingual—full relief + sleep support
• Breakthrough: Vape as needed for acute flares

Evidence: CBD pain data [4], delta-9 pain relief [13], caryophyllene CB2 activation [24], THCa COX-2 inhibition [12]

Massachusetts context: Chronic pain patients in rural areas often drive hours to Worcester or Boston for pain clinics. Our direct delivery eliminates that burden.

For Sleep Disorders (Boston Insomniacs, Shift Workers)

• Bedtime: 1–2 mL sublingual
• 2 mL = 50 mg CBN—dosage investigated in recent literature
• 1 mL = 25 mg CBN—above threshold associated with reduced sleep disturbance

Evidence: CBN sleep studies [16][17], cannabis sleep review [17]

Why it works: Massachusetts has high rates of shift-work disorder (healthcare workers, Logan Airport staff). Our formula delivers precise CBN doses with supporting cannabinoids.

For Anxiety & PTSD (Veterans, Healthcare Workers, Students)

• Daytime functional: 0.3 mL raw sublingual—CBD + CBG without high; stay sharp for Harvard classes or Boston biotech meetings
• Severe episodes: Vape + sublingual combination for rapid + sustained effect

Evidence: CBD anxiolytic data [3], CBG pharmacology [7][8], limonene entourage effect [20]

Massachusetts relevance: High veteran population (especially around Westover ARB), healthcare worker burnout post-COVID, student anxiety in college towns.

The Media Record: Third-Party Validation for Massachusetts Skeptics

Between 2019–2023, ABC13 Houston featured OilWell seven times. For Massachusetts residents wary of online cannabis companies, this is proof:

• September 2019: CBD business boom—Colin’s snake oil quote establishes ethos
• May 2021: Delta-8 investigation—Colin’s blunt honesty aired uncensored
• August 2021: $35,000 COVID vaccine giveaway—documented community action
• October 2021: Delta-8 ban—Colin proactively removed products, warned competitors
• October 2022: Biden pardon—Colin revealed personal conviction history
• April 2023: 4/20 Renaissance—positioned as industry leader

Massachusetts takeaway: This isn’t a fly-by-night brand. It’s a company with sustained, mainstream media credibility in America’s fourth-largest city—credibility that extends to every corner of the Commonwealth.

Frequently Asked Questions: Massachusetts Edition

Q: Is OilWell RSO legal in Massachusetts?
A: Yes. Our product is hemp-derived, contains <0.3% delta-9 THC, and complies with the 2018 Farm Bill. Massachusetts law permits hemp products. You must be 21+. Possession limits apply to activated THC after decarboxylation—understand your local limits.

Q: Can I use this if I have a Massachusetts medical marijuana card?
A: Absolutely. Our product complements your program. Many medical patients in Worcester and Boston use our RSO alongside dispensary products for the multi-cannabinoid profile and THCa control.

Q: Will this show up on a drug test in Massachusetts?
A: Yes if decarboxylated. Delta-8 THC and converted THCa will trigger positive tests. No if used raw—THCa alone won’t. Many Massachusetts employers (especially healthcare, transportation) test. Use raw form if employed in sensitive sectors.

Q: How does this compare to what I’d buy at a dispensary in Northampton?
A: Dispensary RSO is typically THC-only, ~600–900 mg delta-9 per gram, no terpenes, no THCa control. Ours: 16,590 mg total cannabinoids across 7 compounds, 5% live terpenes, patient-controlled psychoactivity. Plus, we ship to your door in Amherst—no dispensary trip.

Q: Can I make this myself in my Massachusetts home?
A: Yes. The complete formula is published above. Source isolates/distillates from reputable suppliers. Use food-grade MCT oil. Follow our decarboxylation instructions. Be precise—Bentley’s life depended on it.

Q: Is this safe for my elderly parent in Cape Cod?
A: Start low (0.25 mL). Monitor for drowsiness. Consult their physician—especially if they’re on multiple medications common in geriatric patients. Our raw form is ideal for daytime use without cognitive impairment.

Q: What if I live in a small Massachusetts town with no dispensary?
A: We ship statewide. From Charlemont to Chatham, Provincetown to Peru (yes, there’s a Peru, MA), we deliver.

The Massachusetts Call to Action

If you’re a Massachusetts resident struggling with pain, cancer treatment side effects, PTSD, insomnia, or any condition where cannabinoids might help, you have options.

Option 1: Order from OilWell

• Visit our RSO Guide: https://oilwellcbd.com/thca-rick-simpson-oil-rso-by-oilwell-cannabis-of-houston-texas/
• Call (832) 416-2816—ask about Massachusetts shipping
• Email [email protected]—mention your Massachusetts town for delivery timing
• Follow @oilwellcbd on Instagram for Massachusetts customer features

Option 2: Make Your Own

• Use the formulas published above
• Source from reputable suppliers—Massachusetts has a growing hemp processing industry
• Be precise, be safe, test if possible

Option 3: Combine with Massachusetts Resources

• Discuss with your oncologist at Dana-Farber or Mass General
• Integrate with pain management at UMass Memorial
• Connect with veteran support groups in Worcester or Lowell
• Consult a cannabis-knowledgeable physician in Cambridge

Final Word to Massachusetts

Massachusetts is a state of innovators, researchers, and compassionate people. You legalized medical cannabis before most of the country. You have world-class hospitals and some of the most educated consumers in America. You deserve cannabis education that matches your sophistication.

OilWell Cannabis was built from desperation, perfected through a decade of love for a dying dog, and validated by mainstream media over four years. We’re not here to mythologize Rick Simpson or claim cancer cures. We’re here to give you the most complete, evidence-based, transparently sourced RSO formula available—backed by 29 peer-reviewed citations, open-source recipes, and a founder who’s lived what you’re living.

From the South Coast to the North Shore, from the Merrimack Valley to the Pioneer Valley, we ship to you. Legally. Safely. Honestly.

Order today. Or make it yourself. But don’t settle for less than the full story.

References

1. National Center for Complementary and Integrative Health. Cannabis Marijuana and Cannabinoids: What You Need To Know. NIH/NCCIH. Accessed March 2026. Available at: https://www.nccih.nih.gov/health/cannabis-marijuana-and-cannabinoids-what-you-need-to-know
2. Talwar A, Estes E, Aparasu R, Reddy DS. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. Exp Neurol. 2023;359:114238. PMID: 36206805.
3. Han K, Wang JY, Wang PY, Peng YC. Therapeutic potential of cannabidiol CBD in anxiety disorders: A systematic review and meta-analysis. Psychiatry Res. 2024;339:116049. PMID: 38924898.
4. Cásedas G, Yarza-Sancho M, López V. Cannabidiol CBD: A systematic review of clinical and preclinical evidence in the treatment of pain. Pharmaceuticals Basel. 2024;17(11):1438. PMID: 39598350.
5. Ranum RM, Whipple MO, Croghan I, Bauer B, Toussaint LL, Vincent A. Use of cannabidiol in the management of insomnia: A systematic review. Cannabis Cannabinoid Res. 2023;8(2):213-229. PMID: 36149724.
6. Lo LA, Christiansen A, Eadie L, Strickland JC, Kim DD, Boivin M, Barr AM, MacCallum CA. Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis. J Intern Med. 2023;293(6):724-752. PMID: 36912195.
7. Nachnani R, Raup-Konsavage WM, Vrana KE. The pharmacological case for cannabigerol. J Pharmacol Exp Ther. 2021;376(2):204-212. PMID: 33168643.
8. Li S, Li W, Malhi NK, Huang J, Li Q, Zhou Z, Wang R, Peng J, Yin T, Wang H. Cannabigerol CBG: A comprehensive review of its molecular mechanisms and therapeutic potential. Molecules. 2024;29(22):5471. PMID: 39598860.
9. Tagen M, Klumpers LE. Review of delta-8-tetrahydrocannabinol delta8 THC: Comparative pharmacology with delta9 THC. Br J Pharmacol. 2022;179(15):3915-3933. PMID: 35523678.
10. LoParco CR, Rossheim ME, Walters ST, Zhou Z, Olsson S, Sussman SY. Delta-8 tetrahydrocannabinol: A scoping review and commentary. Addiction. 2023;118(6):1011-1028. PMID: 36710464.
11. Abdel-Kader MS, Radwan MM, Metwaly AM, Eissa IH, Hazekamp A, ElSohly MA. Chemistry and pharmacology of Delta-8-Tetrahydrocannabinol. Molecules. 2024;29(6):1249. PMID: 38542886.
12. Moreno-Sanz G. Can You Pass the Acid Test? Critical review and novel therapeutic perspectives of delta9-Tetrahydrocannabinolic Acid A. Cannabis Cannabinoid Res. 2016;1(1):124-130. PMID: 28861488.
13. McDonagh MS, Morasco BJ, Wagner J, Ahmed AY, Fu R, Kansagara D, Chou R. Cannabis-based products for chronic pain: A systematic review. Ann Intern Med. 2022;175(8):1143-1153. PMID: 35667066.
14. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327-360. PMID: 12648025.
15. Rittiphairoj T, Leslie L, Oberste JP, Yim TW, Tung G, Bero L, Riggs P, Hutchison K, Samet J, Li T. High-concentration delta-9-tetrahydrocannabinol cannabis products and mental health outcomes: A systematic review. Ann Intern Med. 2025;178(10):1429-1440. PMID: 40854216.
16. Corroon J. Cannabinol and sleep: Separating fact from fiction. Cannabis Cannabinoid Res. 2021;6(5):366-371. PMID: 34468204.
17. Lavender I, Garden G, Grunstein RR, Yee BJ, Hoyos CM. Using cannabis and CBD to sleep: An updated review. Curr Psychiatry Rep. 2024;26(12):712-727. PMID: 39612156.
18. Sepulveda DE, Vrana KE, Kellogg JJ, Bisanz JE, Desai D, Graziane NM, Raup-Konsavage WM. The potential of cannabichromene as a therapeutic agent. J Pharmacol Exp Ther. 2024;391(2):206-213. PMID: 38777605.
19. Zagožen M, Čerenak A, Kreft S. Cannabigerol and cannabichromene in Cannabis sativa L. Acta Pharm. 2021;71(3):355-364. PMID: 36654096.
20. André R, Gomes AP, Pereira-Leite C, Marques-da-Costa A, Monteiro Rodrigues L, Sassano M, Rijo P, Costa MDC. The entourage effect in cannabis medicinal products: A comprehensive review. Pharmaceuticals Basel. 2024;17(11):1543. PMID: 39598452.
21. Anandakumar P, Kamaraj S, Vanitha MK. D-limonene: A multifunctional compound with potent therapeutic effects. J Food Biochem. 2021;45(1):e13566. PMID: 33289132.
22. Ogueta IA, Brared Christensson J, Giménez-Arnau E, Brans R, Wilkinson M, Stingeni L, Foti C, Aerts O, Svedman C, Gonçalo M, Giménez-Arnau A. Limonene and linalool hydroperoxides review: Pros and cons for routine patch testing. Contact Dermatitis. 2022;87(1):1-12. PMID: 35122274.
23. Surendran S, Qassadi F, Surendran G, Lilley D, Heinrich M. Myrcene: What are the potential health benefits of this flavouring and aroma agent? Front Nutr. 2021;8:699666. PMID: 34350208.
24. Hashiesh HM, Sharma C, Goyal SN, Sadek B, Jha NK, Al Kaabi J, Ojha S. A focused review on CB2 receptor-selective pharmacological properties and therapeutic potential of beta-caryophyllene, a dietary cannabinoid. Biomed Pharmacother. 2021;140:111639. PMID: 34091179.
25. Weston-Green K, Clunas H, Jimenez Naranjo C. A review of the potential use of pinene and linalool as terpene-based medicines for brain health: Discovering novel therapeutics in the flavours and fragrances of cannabis. Front Psychiatry. 2021;12:583211. PMID: 34512404.
26. Dos Santos ÉRQ, Maia JGS, Fontes-Júnior EA, do Socorro Ferraz Maia C. Linalool as a therapeutic and medicinal tool in depression treatment: A review. Curr Neuropharmacol. 2022;20(6):1073-1092. PMID: 34544345.
27. Dalavaye N, Nicholas M, Pillai M, Erridge S, Sodergren MH. The clinical translation of alpha-humulene: A scoping review. Planta Med. 2024;90(9):664-674. PMID: 38626911.
28. Menezes IO, Scherf JR, Martins AOBPB, Ramos AGB, Quintans JSS, Coutinho HDM, Ribeiro-Filho J, de Menezes IRA. Biological properties of terpinolene evidenced by in silico, in vitro and in vivo studies: A systematic review. Phytomedicine. 2021;93:153768. PMID: 34634744.
29. Russo EB. Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344-1364. PMID: 21749363.

Rick Simpson References

RS1. Simpson R. Phoenix Tears: The Rick Simpson Story. Simpson RamaDur LLC; 2012.
RS2. Laurette C, director. Run From The Cure: The Rick Simpson Story . 2005. Distributed via phoenixtears.ca and online platforms.
RS3. Simpson R. Instructions and dosing information published on phoenixtears.ca. Multiple dates. Accessed March 2026.
RS4. Velasco G, Sánchez C, Guzmán M. Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer. 2012;12(6):436-444. PMID: 22555283.
RS5. Guzmán M, Duarte MJ, Blázquez C, et al. A pilot clinical study of delta-9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer. 2006;95(2):197-203. PMID: 16804518.
RS6. National Cancer Institute. Cannabis and Cannabinoids (PDQ) — Health Professional Version. NIH/NCI. Updated 2024. Available at: https://www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq

Contact OilWell Cannabis
Phone: (832) 416-2816
Email: [email protected]
Address: 810 Richmond Ave, Houston, TX 77006 (Montrose)
Instagram: @oilwellcbd

Order RSO for Massachusetts delivery: https://oilwellcbd.com/thca-rick-simpson-oil-rso-by-oilwell-cannabis-of-houston-texas/

Disclaimer for Massachusetts residents: These products have not been evaluated by the FDA. They are not intended to diagnose, treat, cure, or prevent any disease. Consult your Massachusetts-licensed physician before use, especially if receiving care at any Massachusetts medical institution. Age 21+ only. Keep out of reach of children. May cause drowsiness. Do not operate vehicles or machinery while using psychoactive cannabinoids. Customer assumes legal responsibility for decarboxylation decisions. Void where prohibited by law.